Category: HIRN Specific

HIRN CBDS Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas (RFA-DK-23-007)

HIRN Consortium on Targeting and Regeneration (HIRN-CTAR) (RFA-DK-22-009)

Purpose: This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with­ the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Learn more HERE.

Deadlines:
Application: July 9, 2024
Earliest Start Date: April 2025

NIH Director’s New Innovator Award Program (RFA-RM-24-003)

NIH Director’s New Innovator Award Program (RFA-RM-24-003)

Purpose: The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIH’s Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director’s New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.

Learn more HERE.

Deadlines:
Application: August 19, 2024
Earliest Start Date: July 2025